Search





Search





Markets
/
Stocks
/
nasdaq-erna
/

Eterna Therapeutics Inc

ERNA

Add to Watchlist

13.630USD

+4.070+42.57%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

15.90MMarket Cap

LossP/E TTM



Eterna Therapeutics Inc

13.630

+4.070+42.57%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Eterna Therapeutics Inc

Currency: USD Updated: 2026-05-15

Key Insights

Eterna Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 197 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eterna Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

197 / 382

Overall Ranking

380 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Eterna Therapeutics Inc Highlights

StrengthsRisks

Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.

Undervalued

The company’s latest PE is -0.08, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 23.70K shares, increasing 3.06% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.31.

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Eterna Therapeutics Inc is 6.52, ranking 232 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.52

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.46

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Eterna Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Eterna Therapeutics Inc is 5.97, ranking 334 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.08, which is -134.14% below the recent high of 0.03 and -4355.92% above the recent low of -3.50.

Score

Industry at a Glance

Previous score

5.97

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 197/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

No earnings forecast score is currently available for Eterna Therapeutics Inc. The Biotechnology & Medical Research industry's average is 8.13.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Eterna Therapeutics Inc is 9.60, ranking 4 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 18.61 and the support level at 5.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.61

Change

1.99

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

1.914

Buy

RSI(14)

72.483

Buy

STOCH(KDJ)(9,3,3)

71.127

Neutral

ATR(14)

2.316

High Vlolatility

CCI(14)

130.898

Buy

Williams %R

17.721

Overbought

TRIX(12,20)

3.206

Sell

StochRSI(14)

58.816

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

10.910

Buy

MA10

8.367

Buy

MA20

6.483

Buy

MA50

6.153

Buy

MA100

13.781

Sell

MA200

24.267

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Eterna Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 2.03%, representing a quarter-over-quarter increase of 45.79%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Cherington (Charles)

6.78M

+143.91%

Freebird Partners LP

735.41K

Regolith Capital Investments LP

558.53K

+1.98%

Halpern (John D)

661.11K

+69.32%

Corient Private Wealth LLC

438.09K

IAF, LLC

315.78K

+45.50%

Purchase Capital LLC

66.67K

Singer (Nicholas Jason)

54.00K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Eterna Therapeutics Inc is 1.45, ranking 301 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.17. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Eterna Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.